Sleep Study Prior Authorization: Aetna vs. UnitedHealthcare—A Billing Specialist’s Guide
This article provides a practical, policy-driven roadmap for claims and billing teams navigating sleep study prior authorization with Aetna and UnitedHealthcare. It details Texas-specific submission requirements, highlights the clinical triggers for bypassing home sleep apnea testing (HSAT), and clarifies when in-lab polysomnography (PSG) is covered. Aetna offers explicit criteria for skipping HSAT—such as specific comorbidities, sleep disorders, or functional limitations—while UnitedHealthcare’s national policies do not specify such triggers, requiring plan-specific review. The article also explains the exact AHI and time thresholds for split-night titration under Aetna, contrasted with UHC’s more flexible, guideline-based approach. Both payers align with AASM recommendations: after a negative or inconclusive HSAT, in-lab PSG is medically necessary if clinical suspicion remains high. Actionable guidance is provided for documentation, submission, and appeals, emphasizing the importance of using payer policy language and retaining records. Billing teams will gain clear, actionable strategies to reduce denials, ensure compliance, and streamline the prior authorization process for sleep studies.
Navigating Sleep Study Prior Authorization: A Practical Guide for Billing Teams
Executive Summary
Sleep study prior authorization is a complex, high-stakes process for billing and claims teams, especially when working with major payers like Aetna and UnitedHealthcare. Understanding the nuances of coverage criteria, documentation requirements, and payer-specific clinical triggers is essential for timely approvals and clean claims. This guide synthesizes the latest policy requirements for sleep studies—including Home Sleep Apnea Testing (HSAT), in-lab polysomnography (PSG), and split-night titration—so your team can avoid denials and streamline workflows.
Understanding Prior Authorization for Sleep Studies
Why Prior Authorization Matters
Prior authorization (PA) is more than a checkbox—it's a gatekeeper for reimbursement. Both Aetna and UnitedHealthcare require PA for in-lab sleep studies (CPT 95810, 95811), but not for most home sleep tests. Missing a required PA can mean denied claims and delayed patient care .
Texas-Specific Requirements (Aetna)
In Texas, Aetna must accept the Texas Standardized Prior Authorization Request Form for any service requiring PA. Submissions can be made by fax, mail, or electronically, but electronic submission via Availity or Aetna's portal is strongly recommended for speed and tracking . Always include complete provider information, clinical documentation, and service details to avoid delays .
When Can You Skip HSAT and Go Straight to In-Lab PSG?
Aetna: Clear Clinical Triggers
Aetna allows bypassing HSAT and proceeding directly to in-lab PSG (95810) when:
- The patient has comorbidities that degrade HSAT accuracy, such as:
- Moderate/severe pulmonary disease (with nocturnal O2 or daytime hypercapnia)
- Neuromuscular disease
- Stroke with residual respiratory effects
- Epilepsy
- Congestive heart failure (NYHA III/IV or LVEF <45%)
- Pulmonary hypertension
- Chronic opioid use
- Super obesity (BMI >45, or BMI >35 with hypoventilation or inability to lie flat)
- The patient has comorbid sleep disorders (e.g., periodic limb movement disorder, parasomnias, narcolepsy, central/complex sleep apnea, severe insomnia)
- The patient lacks the mobility or dexterity to use HSAT equipment safely at home
Action: Document the qualifying comorbidity or limitation in your PA request using Aetna's policy language for best results.
UnitedHealthcare: No Universal List
UnitedHealthcare does not provide a nationwide list of comorbidities or limitations that allow bypassing HSAT for in-lab PSG. The only explicit list is for New Jersey Medicaid, which cannot be generalized to Texas or commercial plans . For most UHC plans, in-lab PSG requires PA, and HSAT is covered without PA, but clinical triggers for skipping HSAT are not specified in the available documents .
Action: For Texas or commercial UHC plans, obtain the plan-specific medical policy before requesting in-lab PSG without prior HSAT.
Split-Night Titration: When Can You Convert?
Aetna: Explicit AHI and Time Thresholds
Aetna's policy is clear: you can convert a diagnostic PSG to a split-night titration (95811) if the Apnea-Hypopnea Index (AHI) is greater than 15 during the first 2 hours of the study. If AHI is ≤15, a separate titration night is required .
- Minimum diagnostic recording: 2 hours, or >30 events (no symptoms) / >10 events (with symptoms) if <2 hours
Action: Ensure your sleep lab documentation supports these thresholds for clean billing.
UnitedHealthcare: No Published Threshold
UHC does not specify an AHI or minimum diagnostic time for split-night conversion in its national policies. They recognize split-night studies as medically necessary when attended PSG is indicated, but leave the exact trigger to clinical judgment or AASM guidelines .
Action: Follow your lab's protocol and document the clinical rationale for split-night conversion in the PA submission.
Negative or Inconclusive HSAT: When Is In-Lab PSG Covered?
Both Aetna and UnitedHealthcare align with AASM guidance: if an HSAT is negative, indeterminate, or technically inadequate and OSA is still suspected, an in-lab PSG is medically necessary .
- Do not repeat HSAT after a negative/inconclusive result; go directly to PSG .
Action: In your PA or appeal, state that "HSAT was negative/inconclusive/technically inadequate, but clinical suspicion remains high for OSA," and cite the relevant policy.
Key Takeaways for Billing Teams
- Always verify PA requirements for each payer and plan before scheduling or billing sleep studies.
- Use payer-specific forms and portals for faster processing (e.g., Texas Standardized Form for Aetna).
- Document clinical criteria (comorbidities, AHI thresholds, HSAT results) in the language of the payer's policy.
- Retain all submissions and responses for audit and appeals.
- When in doubt, check the plan-specific policy—especially for UnitedHealthcare, where criteria may vary by state and product.
Staying current with payer policies is the best defense against denials and delays. Make policy language your ally, not your adversary.